Mucinous Adenocarcinoma of the Appendix: Understanding Your Pathology Report

By Jason Wasserman MD PhD FRCPC
August 29, 2026

Mucinous adenocarcinoma of the appendix is a cancer that starts in the gland-forming cells lining the appendix. These cells produce large amounts of mucin, a thick jelly-like substance. A tumor is called mucinous when more than half of it is made up of mucin rather than cells.

What separates this diagnosis from the other mucin-producing tumors of the appendix is how it grows. A low-grade appendiceal mucinous neoplasm (LAMN) and a high-grade appendiceal mucinous neoplasm (HAMN) push outward with a broad, rounded front. A mucinous adenocarcinoma burrows into the wall, destroying the normal layers as it goes. That destructive growth is what makes it a cancer.

Because it invades, this tumor can also do things the other two rarely do. It can spread to lymph nodes, and it more often produces peritoneal disease containing cells capable of growing. Appendiceal cancers of all types are uncommon, affecting roughly one or two people per million each year.

What causes mucinous adenocarcinoma of the appendix?

The cause is not known. These tumors occur by chance rather than being inherited, and no environmental or lifestyle cause has been identified. Most are diagnosed in people in their fifties and sixties, and men and women are affected about equally.

Many carry a mutation in KRAS, a gene that drives cells to keep dividing. Mutations in GNAS are less common here than in LAMN and HAMN, and their absence helps separate adenocarcinoma from those tumors. Higher-grade tumors often carry additional changes, such as TP53 mutations.

These tumors usually do not show mismatch repair deficiency or the BRAF changes seen in some colon cancers. Testing may still be performed, since the results occasionally affect treatment options for advanced disease.

What are the symptoms of mucinous adenocarcinoma of the appendix?

Symptoms often resemble appendicitis, with pain in the lower right abdomen, fever, nausea, or vomiting. Many tumors are found during surgery performed for exactly that reason.

Others notice slower changes, including bloating, a change in bowel habits, or unexplained weight loss. If mucin and tumor cells have spread into the abdomen, the picture is different again. The abdomen may swell over months, a new hernia may appear at the navel or groin, or a mass may become noticeable. Some tumors cause no symptoms at all and are found during a scan or an operation done for something else.

How is the diagnosis made?

Doctors usually make the diagnosis after removing the appendix, and a pathologist confirms it by examining the tissue under a microscope. The entire appendix is normally examined rather than a sample.

Under the microscope, the pathologist looks for three things together. First, irregular glands burrow into the wall rather than pushing against it. The second is dense, scar-like tissue forming around those glands, called desmoplasia, which is the tissue reacting to invasion. The third is large pools of mucin containing clusters and strips of cancer cells.

Finding all three separates a mucinous adenocarcinoma from a LAMN or HAMN. Those tumors can also push mucin through the wall of the appendix, but they do not invade destructively, and they do not provoke desmoplasia. A few other conditions, including diverticular disease of the appendix, can distort the wall and leak mucin, and they are distinguished the same way.

Histologic grade

Grade describes how abnormal the cancer cells look and how they are arranged. For appendiceal tumors, it is one of the most important findings on the whole report. Once disease has spread within the abdomen, grade predicts outcome better than almost anything else.

Grade is reported on a three-point scale, though in practice mucinous adenocarcinoma falls into the upper two.

G1, well differentiated. Reserved for low-grade tumors without destructive invasion. In practice, this describes a LAMN rather than an adenocarcinoma.
G2, moderately differentiated. The usual grade for a mucinous adenocarcinoma. The cells look clearly abnormal, and the tumor invades, but there are few or no signet ring cells.
G3, poorly differentiated. Assigned when signet ring cells make up more than about 10% of the tumor cells and are invading the tissue.

A signet ring cell is a cancer cell so full of mucin that the mucin flattens the nucleus against the edge of the cell. The result looks like a ring with a stone set in it. When these cells make up more than half the tumor, the diagnosis becomes signet ring cell carcinoma, which behaves less favorably again.

One point to note is whether your report mentions signet ring cells. Dying cells and immune cells floating in mucin can closely resemble true signet ring cells. Pathologists distinguish the two, and only genuine signet ring cells invading the tissue raise the grade.

Tumor extension into the wall of the appendix

Your report will describe how deeply the cancer has grown through the wall of the appendix. This determines the T category.

T1. The cancer has reached the submucosa, the supporting layer just beneath the lining.
T2. The cancer has reached the muscularis propria, the wall’s thick muscle layer.
T3. The cancer has passed through the muscle into the fatty tissue beneath the outer surface.
T4a. The cancer, or mucin-containing cancer cells, has reached the serosa, the appendix’s outer surface.
T4b. The cancer has grown directly into a neighboring organ or structure, such as the cecum, the small intestine, or the abdominal wall.

Reaching the serosa matters because it is the last layer before the abdominal cavity. Once the cancer reaches the serosa, cells can shed directly into the abdomen and settle on other surfaces.

Mucin outside the appendix

When mucin escapes the appendix, the pathologist examines it to determine whether tumor cells are present.

Acellular mucin. Mucin is present outside the appendix, but no tumor cells are found. Without cells, the material generally cannot grow. This is staged M1a.
Mucin-containing tumor cells. Living cancer cells are present in mucin outside the appendix. This is staged M1b, and it is the more common finding with an adenocarcinoma.
Spread outside the abdomen. Cancer found in the liver, lungs, or another distant site is staged M1c. This is uncommon but happens more often with this diagnosis than with LAMN or HAMN.

Confirming that mucin is acellular requires examining a great deal of tissue, because cells can be sparse and flattened at the edge of a mucin pool. This is part of why these specimens take longer to report than a routine appendix.

Lymphovascular invasion

Lymphovascular invasion means cancer cells were seen inside small blood vessels or lymphatic channels. These vessels are routes out of the appendix, so their involvement indicates the cancer has found a way to travel.

Finding it raises the estimated risk that cancer has already reached lymph nodes or elsewhere. Your doctor weighs this finding when deciding on further surgery or chemotherapy. Not finding it is a favorable sign but does not rule out spread entirely.

Perineural invasion

Perineural invasion means cancer cells were seen surrounding or tracking along a nerve. Nerves run through the tissues around the appendix like small cables, and cancer that follows them can extend further than expected.

Its presence is associated with a higher risk of the cancer returning near the original site, and it is another finding that contributes to decisions about additional treatment.

Margins

The margin is the cut edge of the tissue removed at surgery. For an appendectomy, the margin that matters most is the base of the appendix, where it was separated from the large intestine.

Negative margin. No cancer cells reach the cut edge. The tumor appears to have been removed completely.
Positive margin. Cancer cells extend to the cut edge, so tumor may remain at the junction with the bowel.

Margin status carries real weight for this diagnosis. A positive margin is linked to worse outcomes across appendiceal cancers, and it commonly leads to a further operation to remove more tissue.

Lymph nodes

Lymph nodes are small immune organs that filter fluid from the tissues. Unlike LAMN and HAMN, mucinous adenocarcinoma can spread through lymphatic channels, so lymph node status is an important part of the report.

An appendectomy alone usually removes few or no lymph nodes. Assessing them properly requires a larger operation that takes the nearby colon and its lymph nodes as well, which is one of the main reasons that operation is often recommended.

The report gives the number of nodes containing cancer out of the total examined. The N category follows from that count:

N0. No cancer in any node examined.
N1. Cancer in one to three nodes. Your report may subdivide this by the exact number involved, or note tumor deposits sitting in nearby fat without a recognizable node.
N2. Cancer in four or more nodes.

Node involvement raises the stage and is one of the strongest arguments for post-surgery chemotherapy.

Pathologic stage (pTNM)

The stage combines the findings above into a single summary. The letter p means the stage is based on tissue examined under a microscope rather than on imaging.

Stage I. T1 or T2, no node involvement, no spread.
Stage IIA. T3, no node involvement, no spread.
Stage IIB. T4a, no node involvement, no spread.
Stage IIC. T4b, no node involvement, no spread.
Stage III. Cancer in regional lymph nodes, with no spread beyond them.
Stage IVA. Acellular mucin in the abdomen at any grade, or mucin-containing low-grade tumor cells.
Stage IVB. Mucin in the abdomen containing G2 or G3 tumor cells.
Stage IVC. Spread beyond the abdominal lining.

Grade determines the stage in one specific place. When tumor cells are present in the abdomen, low-grade cells give stage IVA and higher-grade cells give stage IVB. Most staging systems stage based on the extent of the disease alone, so patients comparing their report with general cancer information often find this confusing.

Pseudomyxoma peritonei

Pseudomyxoma peritonei, usually shortened to PMP, is the name for mucin accumulating inside the abdominal cavity. It gathers where fluid naturally pools, under the diaphragm, in the pelvis, and across the omentum.

PMP arising from an adenocarcinoma differs from PMP arising from a LAMN. It more often contains cells, those cells are more often high grade, and it behaves more like a conventional cancer than like the slow, jelly-filling process seen with low-grade tumors.

Treatment is concentrated in specialized centers. It usually involves cytoreductive surgery, a long operation to remove all visible disease from the abdomen. Heated chemotherapy is often delivered directly into the abdomen during the same operation, a technique known as HIPEC. Systemic chemotherapy may be given as well, particularly when lymph nodes are involved.

Two measurements guide these decisions. The peritoneal cancer index scores how widely disease is distributed through the abdomen. The completeness of cytoreduction score records how much visible disease the surgeon removed. Both are strong predictors of outcome, and you may see them in your operative or oncology notes rather than on the pathology report.

Prognosis

The outlook varies more widely for this diagnosis than for LAMN or HAMN. Three things drive it: tumor grade, whether the disease has spread within the abdomen, and whether all visible disease can be removed.

Confined to the appendix, completely removed, nodes negative. The outlook is good, and for many people surgery is the only treatment needed.
Spread within the abdomen, treated with cytoreductive surgery and HIPEC. Reported five-year survival is around 55 to 70%, with better results when disease is limited and completely removed.
High-grade disease or incomplete removal. The outlook is considerably less favorable, and treatment often focuses on controlling the disease over time.
Signet ring cell carcinoma. The least favorable group, with reported five-year survival ranging from 20 to 25%.

Published figures for appendiceal adenocarcinoma vary widely, with five-year survival across mixed groups reported anywhere from about 15% to about 60%. Much of that spread reflects changing definitions rather than real differences between patients, since older studies grouped together tumors that would now be separated into LAMN, HAMN, and adenocarcinoma. Figures from specialist centers are generally better than older published numbers suggest.

Better outcomes are associated with limited disease spread in the abdomen, a normal or near-normal CEA blood level, and complete removal of all visible tumor.

What happens after this diagnosis?

Treatment for this diagnosis is more involved than for the other appendiceal mucinous tumors, and it usually involves more than one specialist.

A larger operation called a right hemicolectomy is often recommended after the appendix has been removed. This takes the right side of the colon along with the lymph nodes that drain the area. It serves two purposes: obtaining a clear margin where the appendix met the bowel, and providing enough lymph nodes to assess node status properly. Your surgeon will weigh this against the tumor depth, grade, and your overall health.

Chemotherapy after surgery is often discussed when lymph nodes contain cancer. Its role for node-negative disease is less settled, and practice varies. When disease has spread within the abdomen, referral to a surgical oncologist specializing in peritoneal disease is usual, and cytoreductive surgery with HIPEC may be considered.

Follow-up typically combines clinic visits, imaging, and blood tests for tumor markers such as CEA. Your pathology report is one of several factors the team weighs, and it shapes what happens next.

Questions to ask your doctor

What grade was my tumor, and were any signet ring cells present?
How deeply had the cancer grown into the wall of the appendix?
Was the margin at the base of the appendix clear?
How many lymph nodes were examined, and how many contained cancer?
Was any mucin found outside the appendix, and did it contain tumor cells?
What was my overall stage?
Was lymphovascular or perineural invasion present?
Do you recommend a right hemicolectomy, and what would it add?
Is chemotherapy being considered, and what would it be for?
Should I be referred to a center that specializes in peritoneal surface tumors?
Would cytoreductive surgery or HIPEC be appropriate in my case?
How will I be followed, and how often?
What symptoms should prompt me to call you between visits?